Scholarlink

Purpose <p>With increasing life expectancy, the clinical role of radiotherapy in cancer patients aged ≥ 90 years warrants systematic evaluation. This study aimed to assess treatment patterns, safety, and outcomes of radiotherapy in the super-elderly at a tertiary cancer center.</p> Methods <p>We retrospectively analyzed 119 patients aged ≥ 90 years who underwent radiotherapy between 2007 and 2025. Patient characteristics, treatment modalities, adverse events, and survival were evaluated. Univariate and multivariate Cox regression analyses were performed to identify prognostic factors.</p> Results <p>The median age was 91 years, and 71% of patients had ECOG performance status (PS) 0–1. Radiotherapy was delivered with curative intent in 69% of cases. Advanced techniques such as stereotactic radiotherapy (SRT), intensity-modulated radiotherapy (IMRT), and brachytherapy (BT) were used in 59% of patients. Hypofractionated schedules (≤ 10 fractions) were applied in 66% of cases. Treatment completion rate was 95%, with grade ≥ 3 adverse events observed in only 3% of patients. Median overall survival was 31.2 months. On multivariate analysis, PS was the only independent prognostic factor for survival.</p> Conclusion <p>Radiotherapy for patients aged ≥ 90 years can be delivered safely and effectively in appropriately selected individuals, particularly when utilizing tailored approaches such as SRT, IMRT, or BT. Even among patients treated with palliative intent, meaningful local control and symptom relief were achievable. These findings suggest that chronological age alone should not preclude the use of radiotherapy; however, clinical decisions should be guided by individual patient factors such as performance status, functional reserve, and overall clinical context.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radiotherapy strategies for nonagenarian cancer patients at a tertiary cancer center

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Kae Okuma,
  • Ayaka Nagao,
  • Koji Inaba,
  • Tairo Kashihara,
  • Kana Takahashi,
  • Madoka Sakuramachi,
  • Akane Yoshiba,
  • Akikazu Kobori,
  • Shoki Nakamura,
  • Hiroshi Igaki

摘要

Purpose

With increasing life expectancy, the clinical role of radiotherapy in cancer patients aged ≥ 90 years warrants systematic evaluation. This study aimed to assess treatment patterns, safety, and outcomes of radiotherapy in the super-elderly at a tertiary cancer center.

Methods

We retrospectively analyzed 119 patients aged ≥ 90 years who underwent radiotherapy between 2007 and 2025. Patient characteristics, treatment modalities, adverse events, and survival were evaluated. Univariate and multivariate Cox regression analyses were performed to identify prognostic factors.

Results

The median age was 91 years, and 71% of patients had ECOG performance status (PS) 0–1. Radiotherapy was delivered with curative intent in 69% of cases. Advanced techniques such as stereotactic radiotherapy (SRT), intensity-modulated radiotherapy (IMRT), and brachytherapy (BT) were used in 59% of patients. Hypofractionated schedules (≤ 10 fractions) were applied in 66% of cases. Treatment completion rate was 95%, with grade ≥ 3 adverse events observed in only 3% of patients. Median overall survival was 31.2 months. On multivariate analysis, PS was the only independent prognostic factor for survival.

Conclusion

Radiotherapy for patients aged ≥ 90 years can be delivered safely and effectively in appropriately selected individuals, particularly when utilizing tailored approaches such as SRT, IMRT, or BT. Even among patients treated with palliative intent, meaningful local control and symptom relief were achievable. These findings suggest that chronological age alone should not preclude the use of radiotherapy; however, clinical decisions should be guided by individual patient factors such as performance status, functional reserve, and overall clinical context.